CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0220-000 |
|---|---|
| Brand Name | Sarclisa |
| Generic Name | Isatuximab |
| Strength | 100mg and 500mg |
| Tumour Type | Myeloma |
| Indication | Multiple Myeloma |
| Funding Request | Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | No |
| NOC Date | April 29, 2020 |
| Manufacturer | Sanofi Genzyme |
| Sponsor | Sanofi Genzyme |
| Submission Date | August 17, 2020 |
| Submission Deemed Complete | August 31, 2020 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | August 31, 2020 |
| Check-point meeting | October 28, 2020 |
| pERC Meeting | January 21, 2021 |
| Initial Recommendation Issued | February 4, 2021 |
| Feedback Deadline ‡ | February 19, 2021 |
| pERC Reconsideration Meeting | March 18, 2021 |
| Final Recommendation Issued | April 1, 2021 |
| Notification to Implement Issued | April 19, 2021 |
| Therapeutic Area | Multiple Myeloma |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
